Severe Acute Respiratory News and Research

RSS

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

The potential role of Ginkgo biloba L. folium extract in the management of COVID-19

Researchers explored the effectiveness of Ginkgo biloba L. folium extract (EGb) in the management of COVID-19 severity.

13 Jun 2022

Innate and adaptive immune responses to SARS-CoV-2 infection in older golden hamsters

Researchers assessed the variation in SARS-CoV-2 manifestation with age.

13 Jun 2022

Smartwatches used to monitor short-term effects of 4th BNT162b2 booster shot

In a recent study posted to the medRxiv* pre-print server, researchers in Israel compared the short-term effects of the first and second booster doses of messenger ribonucleic acid (mRNA-based) coronavirus disease 2019 (COVID-19) vaccine BNT162b2.

13 Jun 2022

Population-level big data reveals COVID-19 phenotypes

A recent study published in The Lancet Digital Health journal assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection trajectories in England utilizing electronic health records (EHRs).

13 Jun 2022

SARS-CoV-2 BA.4/5 variants escape vaccine and BA.1 infection induced antibodies

In a recent work published in the Cell journal, investigators examined the severe acute respiratory syndrome coronavirus (SARS-CoV-2) Omicron BA.5/4 variants escape from neutralizing antibodies induced by SARS-CoV-2 vaccines and natural infection.

13 Jun 2022

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

In a recent study published in the journal PNAS, researchers demonstrated higher comparative efficacy of the intranasal (IN) route of coronavirus disease 2019 (COVID-19) vaccine administration versus intramuscular route in mice.

12 Jun 2022

Co-circulation of adenovirus 40/41 and SARS-CoV-2 and emergence of hepatitis cases in children

In a recent study posted to the medRxiv* pre-print server, KU Leuven researchers investigated whether there was an association between the intensity of the co-circulation of adenovirus (AdV) 40/41 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the number of hepatitis cases of unknown origin emerging in Belgium.

12 Jun 2022

Super-immunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain

A recent study published in Cell Reports reported the development of pan-sarbecovirus nanobodies (psNbs).

10 Jun 2022

Study investigates SARS-CoV-2 escape from nirmatrelvir

Researchers assessed SARS-CoV-2 Alpha, Delta, and Omicron variants’ resistance to nirmatrelvir, a protease inhibitor of SARS-CoV-2.

10 Jun 2022

A suspected zoonotic SARS-CoV-2 transmission from a cat to a human

Researchers investigated a suspected cat to human transmission of SARS-CoV-2.

10 Jun 2022

Association of neuronal and non-neuronal GABA with neuropsychiatric illness in COVID-19 patients

A new study published in the journal Reports focused on the hijacking of the pancreatic, endothelial, and gut GABA by SARS-CoV-2 and its associated pathology along with interventions.

10 Jun 2022

Core body temperature increases host resistance to influenza virus and SARS-CoV-2 infection

A recent article posted to the Research Square* preprint server demonstrated that high body temperature elevates gut microbiota-reliant host resistance against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A viral infection.

10 Jun 2022

Efficacy of BNT162b2 vaccine against SARS-CoV-2 Omicron sublineages and Deltacron

In a recent study posted to the bioRxiv* pre-print server, researchers at the University of Texas Medical Branch, Pfizer Vaccines Research & Development and BioNTech assessed the neutralization titers of sera from individuals vaccinated with the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine and previously infected with the Omicron sublineage BA.1.

10 Jun 2022

Study finds Moderna COVID vaccine efficacy peaks at 94% after 120 days

A recent research letter posted to the JAMA Network Open assessed the durability of immunity conferred by the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA)-1273 vaccine.

10 Jun 2022

Study reports robust immunity to SARS-CoV-2 including Omicron BA.1 for all three primary vaccines

In a recent study posted to the medRxiv* pre-print server, researchers in the United Kingdom investigated the effect of two Pfizer/BioNTech BNT162b2 vaccine doses or Oxford/AstraZeneca AZ1222 coronavirus disease 2019 (COVID-19) vaccination and a subsequent BNT162b2 booster dose in a cohort of healthcare workers (HCWs) over six to nine months.

10 Jun 2022

Severe Acute Respiratory News and Research

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

The potential role of Ginkgo biloba L. folium extract in the management of COVID-19

Innate and adaptive immune responses to SARS-CoV-2 infection in older golden hamsters

Smartwatches used to monitor short-term effects of 4th BNT162b2 booster shot

Population-level big data reveals COVID-19 phenotypes

SARS-CoV-2 BA.4/5 variants escape vaccine and BA.1 infection induced antibodies

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

Co-circulation of adenovirus 40/41 and SARS-CoV-2 and emergence of hepatitis cases in children

Super-immunity in a camelid extensively immunized with the SARS-CoV-2 receptor-binding domain

Study investigates SARS-CoV-2 escape from nirmatrelvir

A suspected zoonotic SARS-CoV-2 transmission from a cat to a human

Association of neuronal and non-neuronal GABA with neuropsychiatric illness in COVID-19 patients

Core body temperature increases host resistance to influenza virus and SARS-CoV-2 infection

Efficacy of BNT162b2 vaccine against SARS-CoV-2 Omicron sublineages and Deltacron

Study finds Moderna COVID vaccine efficacy peaks at 94% after 120 days

Study reports robust immunity to SARS-CoV-2 including Omicron BA.1 for all three primary vaccines

A comparison of SARS-CoV-2 and influenza cytokine storms

Comparison of the strictness of the Shanghai lockdown policy with that of other countries

The presence of residual SARS-CoV-2 antigens in post-convalescent tissues

The effectiveness of non-pharmacological treatments for post-viral syndromes and long COVID

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News